Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259

Article  Google Scholar 

Polaris OC. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403

Article  Google Scholar 

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555

PubMed  Article  Google Scholar 

Franchis DR, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2021;2021:0168

Google Scholar 

Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resistance. 2019;12:745–757

CAS  Article  Google Scholar 

Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438–1450

CAS  PubMed  Article  Google Scholar 

Wang FY, Li B, Li Y, Liu H, Qu WD, Xu HW, et al. Entecavir for patients with hepatitis B decompensated cirrhosis in China: a meta-analysis. Sci Rep. 2016;6:32722

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013;19:6665–6678

PubMed  PubMed Central  Article  CAS  Google Scholar 

Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657–1661

CAS  PubMed  Article  Google Scholar 

Robertson C, Ramsay C, Gurung T, Mowatt G, Pickard R, Sharma P, et al. Practicalities of using a modified version of the Cochrane Collaboration risk of bias tool for randomised and non-randomised study designs applied in a health technology assessment setting. Res Synth Methods. 2014;5:200–211

PubMed  Article  Google Scholar 

Sterne JA, Hernan MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919

PubMed  PubMed Central  Article  Google Scholar 

Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Shiffman M, et al. Adefovir dipivoxil (Adv) Results in a consistent and significant improvement in liver histology and clinical status regardless of baseline Knodell fibrosis score in patients with Hbeag+ Chronic Hepatitis B. Digest Dis Week Abstr Itinerary Planner. 2003;2003:507

Google Scholar 

Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat. 2019;26:818–827

CAS  PubMed  Article  Google Scholar 

Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, et al. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol. 2015;21:9598–9606

CAS  PubMed  PubMed Central  Article  Google Scholar 

Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol. 2009;51:468–474

CAS  PubMed  Article  Google Scholar 

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156:997-1009.e5

PubMed  Article  Google Scholar 

Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti F, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. J Hepatol. 2015;63:1118–1125

CAS  PubMed  Article  Google Scholar 

Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK, et al. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int. 2010;30:1033–1042

PubMed  Article  Google Scholar 

He L, Ye X, Ma J, Li P, Jiang Y, Hu J, et al. Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy. BMC Gastroenterol. 2019;19:101

PubMed  PubMed Central  Article  CAS  Google Scholar 

Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, et al. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. J Gastroenterol Hepatol. 2012;27:1589–1595

CAS  PubMed  Article  Google Scholar 

Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol. 2013;19:6849–6856

PubMed  PubMed Central  Article  Google Scholar 

Liaw YF, Farrell G, Sung JJY, Chow WC, Shue K, Keene ON, et al. Disease progression in chronic hepatitis B with advanced fibrosis or cirrhosis. J Hepatol. 2005;42:183

Google Scholar 

Liu K, Choi J, Le A, Wong VWS, Chan SL, Chl Y, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther. 2019;50:1037–1048

CAS  PubMed  Article  Google Scholar 

Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764

CAS  PubMed  Article  Google Scholar 

Park JY, Kim SG, Tak WY, Yim HJ, Jang BK, Kim MY, et al. Entecavir versus lamivudine for prevention of liver-related events in patients with HBV-related advanced liver disease: a multicenter, prospective study. Journal of hepatology. In Conference: 51st annual meeting of the european association for the study of the liver, international liver congress 2016. Barcelona spain. Conference start: 20160413. Conference end: 20160417. Conference publication: (var.pagings) 2016;64:S595

Wan YM, Li YH, Wu HM, Yang J, Xu Y, Yang LH, et al. Telbivudine versus lamivudine and entecavir for treatment-naïve, decompensated hepatitis B virus-related cirrhosis. Clin Exp Med. 2017;17:233–241

CAS  Article  Google Scholar 

Pan HY, Pen HY, Yan J, Liu H, Chen L, Chen CR, et al. Comparison of clinical outcomes in cirrhotic chronic hepatitis B patients treated with Entecavir or Lamivudine plus Adefovir dipivoxil for 144 weeks. Hepatology. 2013;58:690A

Article  CAS  Google Scholar 

Koklu S, Tuna Y, Gulsen MT, Demir M, Koksal AS, Kockar MC, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11:88–94

CAS  PubMed  Article  Google Scholar 

Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, et al. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014;29:568–575

CAS  PubMed  Article  Google Scholar 

Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61:1809–1820

CAS  PubMed  Article  Google Scholar 

Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, et al. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol. 2021;27:1101–1116

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li L, Liu W, Chen YH, Fan CL, Dong PL, Wei FL, et al. Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study. World J Gastroenterol. 2013;19:8373–8381

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547

CAS  PubMed  Article  Google Scholar 

Jiang JN, Li SH, Su MH, Zhong SH, Wang BJ, Wu XL, et al. The clinical outcomes of the CHB and LC patients treated with long term nucleos(t)ide analogs under whole-course management: a real-life cohort study. J Hepatol. 2014;60:S428

Article  Google Scholar 

Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, et al. Reduced Incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study. J Infect Dis. 2019;219:10–18

CAS  PubMed  Article  Google Scholar 

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107

CAS  PubMed  Article  Google Scholar 

Li T, Qu YD, Wang Y, Lin CL, Yang BH, Wang L. Entecavir and low genetic barrier antiviral agents for hepatocellular carcinoma in hepatitis B Viral Cirrhosis: propensity score matching. JCPSP-J Coll Phys Surg Pak. 2019;29:317–323

Google Scholar 

Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, et al. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data. Liver Int. 2015;35:860–869

CAS  PubMed  Article  Google Scholar 

Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18(457–467): e21

Google Scholar 

Cheinquer H, Raptopoulou-Gigi M, Sarin SK, Tanwandee T, Leung N, Peng CY, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation: week 96 results. Hep Intl. 2011;5:272